Rani Therapeutics News and Activities

Rani Therapeutics is a company listed under the stock ticker RANI (US).

View the org chart displaying its 22 main executives

Most searched biographies at Rani Therapeutics

• Talat Imran, Chief Executive Officer
• Mir Imran, Executive Chairman of the Board
• Abe Bassan, Director

Popular executive movements at Rani Therapeutics

• Nicholas Maestas has joined the company as Chief Financial Officer  (posted on June 29 2026).
• Bradley Krul, Director of Intellectual Property, has left the company  (posted on June 29 2026).
• Svai Sanford, who is Chief Financial Officer will soon leave the company  (posted on May 18 2026).

Click here to view some more movements at Rani Therapeutics

Create your alert
to follow the executive moves at Rani Therapeutics.

Rani Therapeutics has 2,426 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Clearside Biomedical has gone out of its bankruptcy protection  (posted on July 15 2026).
• Attovia Therapeutics has filed its IPO. Its stock ticker will be ATTO. (posted on July 15 2026).
• The new name of ChemoTech is Neem’s Hill. (posted on July 15 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Rani Therapeutics

• Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer - Rani Therapeutics, LLC
• Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates - Rani Therapeutics, LLC
• Presentations | Rani Therapeutics, LLC
• Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025 - Rani Therapeutics, LLC
• Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors - Rani Therapeutics, LLC
• Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules - Rani Therapeutics, LLC
• Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing - Rani Therap
• Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update - Rani Therapeutics, LLC
• View more press releases Close

Social media about Rani Therapeutics

• Rani Therapeutics on Wikipedia, Google News & Yahoo Finance
• Rani Therapeutics on LinkedIn, X (Twitter) & YouTube